We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Safety of CHIR-258 (TKI258) in Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01270906
Recruitment Status : Terminated
First Posted : January 5, 2011
Last Update Posted : January 5, 2011
Chiron Corporation
Information provided by:

Brief Summary:
Phase I dose finding study in solid tumors.

Condition or disease Intervention/treatment Phase
Neoplasms Cancer Tumors Drug: CHIR-258 (TKI258) Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodyniamics of CHIR-258 in Subjects With Advanced Solid Tumor Malignancies
Study Start Date : December 2003
Primary Completion Date : October 2006

Arm Intervention/treatment
Experimental: CHIR-258 (TKI258) Drug: CHIR-258 (TKI258)

Primary Outcome Measures :
  1. dose limiting toxicity (DLT) to define the maximum tolerated dose (MTD). The DLT is defined as treatment related grade 3 or grade 4 adverse events or abnormal lab test that occurred in the first 28 days after start of study drug. [ Time Frame: continuous monitoring for the first 28 days after start of the study medication ]

Secondary Outcome Measures :
  1. characterize pharmacokinetic (PK) profile of study drug after single and repeated doses. The PK profile includes maximum blood concentration (Cmax) and time to reach maximum blood concentration (Tmax). [ Time Frame: day 1 and day 15 at the following timepoints: pre-drug and 30 minutes, 1, 2, 3, 4, 5, 6, and 8 hours after dose ]
  2. Pharmacodynamics (PD) in terms of serine-threonine kinase phosphorylation inhibition in blood before and after dose [ Time Frame: day 1 and day 15 at the following timepoints: pre-drug, 4 and 24 hours after dose ]
  3. Antitumor activity by comparing baseline and post-treatment changes. Tumor assessment will be performed using the Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: baseline and once every two months thereafter ]
  4. urinary metabolic profiling - examination of the ratio of beta-hydroxycortisol/cortisol [ Time Frame: 24 hour urine collection on day 1 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of histologically or cytologically documented, advanced-stage, primary or metastatic solid tumors that are refractory to standard therapy or for which no curative standard therapy exists.
  • Evidence of measurable or evaluable disease.
  • All acute toxic affects of any prior radiotherapy, chemotherapy, or surgical procedures must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 3.0) Grade ≤1; surgery must have occurred at least 28 days prior to study enrollement.
  • Age must be at least 18 years.
  • Last dose of antineoplastic therapy (except for hormonal therapy) must be more than 21 days; subjects may continue to receive luteinizing hormone-releasing hormone analog therapy for prostate cancer.
  • ECOG performance status must be 0 or 1.
  • Life expectancy of at least 3 months.
  • Patient must meet protocol-specified laboratory values.

Exclusion Criteria:

  • Concurrent therapy with any other investigational agent.
  • Intracranial edema, intracranial metastasis, or epidural disease.
  • Pregnant or breastfeeing women. Female subjects must agree to use effective contraception, must be surgically sterile, or must be postmenopausal. Male subjects must agree to use effective contraception or be surgically sterile. The definition of effective contraception will be based on the judgment of the investigator or a designated associate. All at-risk female subjects must have a netative pregnancy test (serum or urine) within 10 days prior to the start of study treatment.
  • Clinically significant cardiac disease (New York Heart Association Class III or IV) including pre-existing arrhythmia, congestive heart failure, cardiomyopathy, or subjects with baseline mean QTc interval greater than 450 msec (males) and 470 msec (females) or grade 2 or higher compromised left ventricular ejection fraction (LVEF) as determined by MUGA or ECHO.
  • Dementia or altered mental status that would prohibit informed consent.
  • Diabetes mellitus (insulin-dependent or -independent disease requiring chronic medication).
  • Previous pericarditis; clinically significant pleural effusion in the previous 12 months or current ascites requiring two or more interventions/month.
  • Malabsorption syndrome or uncontrolled gastrointestinal toxicities (nausea, diarrhea, vomitting) with toxicity greater than NCI CTCAE grade 2.
  • Prior acute or chonic pancreatitis of any etiology.
  • Prior intra-or extra-hepatic biliary obstruction wtihin the previous 12 months or history of malignant obstruction requiring a bilary stent, unless stably treated with no prior obstruction or blockage of the stent.
  • Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study-drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, make the subject inappropriate for this study.

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01270906

United Kingdom
Novartis Investigative Site
Glasgow, United Kingdom
Novartis Investigative Site
Sutton, United Kingdom
Sponsors and Collaborators
Novartis Pharmaceuticals
Chiron Corporation
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: External Affairs, Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01270906     History of Changes
Other Study ID Numbers: CTKI258A2101 (CHIR-258-001)
First Posted: January 5, 2011    Key Record Dates
Last Update Posted: January 5, 2011
Last Verified: January 2011

Keywords provided by Novartis:
CHIR 258
TKI 258
dose finding